Study of MK-4208 for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new pill that may help people with chronic myeloid leukemia (CML) when other treatments have stopped working or caused side effects. It might offer another option for controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic myeloid leukemia (CML) in the chronic phase, which means it has not progressed to a more advanced stage.
- You have tried at least one previous treatment called a tyrosine kinase inhibitor (TKI) and it either failed, did not work well enough, or caused intolerable side effects.
- You are in reasonably good health, able to care for yourself, and can be up and about (ECOG score 0-2).
- Your organs (like liver and kidneys) are working well enough, based on local lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
This study tests a new oral medication for people with chronic myeloid leukemia (CML) who have already tried at least three other treatments without success or with side effects. The goal is to see if this new drug can help control the leukemia.
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.